These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31988141)

  • 1. Death Receptors and Their Ligands in Inflammatory Disease and Cancer.
    Annibaldi A; Walczak H
    Cold Spring Harb Perspect Biol; 2020 Sep; 12(9):. PubMed ID: 31988141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death receptor-ligand systems in cancer, cell death, and inflammation.
    Walczak H
    Cold Spring Harb Perspect Biol; 2013 May; 5(5):a008698. PubMed ID: 23637280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling.
    Sessler T; Healy S; Samali A; Szegezdi E
    Pharmacol Ther; 2013 Nov; 140(2):186-99. PubMed ID: 23845861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer.
    Cullen SP; Martin SJ
    Semin Cell Dev Biol; 2015 Mar; 39():26-34. PubMed ID: 25655947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL-induced signalling and apoptosis.
    MacFarlane M
    Toxicol Lett; 2003 Apr; 139(2-3):89-97. PubMed ID: 12628743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering death receptor ligands for cancer therapy.
    Wajant H; Gerspach J; Pfizenmaier K
    Cancer Lett; 2013 May; 332(2):163-74. PubMed ID: 21236560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
    Kohlhaas SL; Craxton A; Sun XM; Pinkoski MJ; Cohen GM
    J Biol Chem; 2007 Apr; 282(17):12831-41. PubMed ID: 17327223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing tumor necrosis factor receptors to enhance antitumor activities of drugs.
    Muntané J
    Chem Res Toxicol; 2011 Oct; 24(10):1610-6. PubMed ID: 21740002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells.
    Wang J; Hansen K; Edwards R; Van Houten B; Qian W
    Biochem Biophys Res Commun; 2015 Jan; 456(1):7-12. PubMed ID: 25446129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.
    Gerspach J; Wajant H; Pfizenmaier K
    Results Probl Cell Differ; 2009; 49():241-73. PubMed ID: 19142623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting death receptors to fight cancer: from biological rational to clinical implementation.
    Mocellin S
    Curr Med Chem; 2010; 17(25):2713-28. PubMed ID: 20586721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and function of death receptors and their natural ligands in the intestine.
    Sträter J; Möller P
    Ann N Y Acad Sci; 2000; 915():162-70. PubMed ID: 11193573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.
    Kavuri SM; Geserick P; Berg D; Dimitrova DP; Feoktistova M; Siegmund D; Gollnick H; Neumann M; Wajant H; Leverkus M
    J Biol Chem; 2011 May; 286(19):16631-46. PubMed ID: 21454681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of CD95 and the TRAIL death receptors.
    Gerspach J; Pfizenmaier K; Wajant H
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Song JH; Bellail A; Tse MC; Yong VW; Hao C
    J Neurosci; 2006 Mar; 26(12):3299-308. PubMed ID: 16554480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
    Bouralexis S; Findlay DM; Evdokiou A
    Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Product Mediated Regulation of Death Receptors and Intracellular Machinery: Fresh from the Pipeline about TRAIL-Mediated Signaling and Natural TRAIL Sensitizers.
    Shahwar D; Iqbal MJ; Nisa MU; Todorovska M; Attar R; Sabitaliyevich UY; Farooqi AA; Ahmad A; Xu B
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of RASSF1A/MOAP-1 association with death receptors.
    Foley CJ; Freedman H; Choo SL; Onyskiw C; Fu NY; Yu VC; Tuszynski J; Pratt JC; Baksh S
    Mol Cell Biol; 2008 Jul; 28(14):4520-35. PubMed ID: 18474619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of the cannabinoid and death receptor systems - a potential target for future cancer therapies?
    Keresztes A; Streicher JM
    FEBS Lett; 2017 Oct; 591(20):3235-3251. PubMed ID: 28948607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma.
    Gaertner F; Krüger S; Röder C; Trauzold A; Röcken C; Kalthoff H
    Histol Histopathol; 2019 May; 34(5):491-501. PubMed ID: 30375637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.